IMMX Live signals | Maximize Profits with Getagraph.com

BUY 164876 min ago

@ $3.23

Issued: 9 Feb 2024 @ 14:14

Return: -34.57%

Previous signal: Feb 8 - 10:29

Previous signal: Sell

Return: 1.20 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia...

Stats
Today's Volume	39 253.00
Average Volume	142 068
Market Cap	55.73M
EPS	$-0.224 ( 2024-05-10 )
Next earnings date	( $-0.220 ) 2024-08-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.27
ATR14	$0.0120 (0.57%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-20	Adams Helen C.	Buy	74 241	Common Stock
2024-05-15	Adams Helen C.	Buy	87 740	Common Stock
2024-05-20	Rachman Ilya M	Buy	218 359	Common Stock
2024-05-15	Hsu Jason	Buy	25 512	Stock Option (Right to Buy)
2024-05-15	Hsu Jason	Buy	21 587	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 83 transactions
Buy: 8 056 766 \| Sell: 879 400

Volume Correlation

Long: -0.17 (neutral)

Short: 0.40 (neutral)

Signal:(59.342) Neutral

Immix Biopharma, Inc. Correlation

10 Most Positive Correlations
IRBT	0.966
LGVN	0.962
SIFY	0.96
WALD	0.957
RDHL	0.957
AXDX	0.956
PLL	0.956
INVZ	0.955
CNSP	0.955
EVOK	0.954

10 Most Negative Correlations
ADTH	-0.939
FLXS	-0.928
FSEA	-0.904
INBKZ	-0.902
SILK	-0.892
OXSQ	-0.892
NTNX	-0.891
APXI	-0.889
AGNCP	-0.888
HQY	-0.887

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Immix Biopharma, Inc. Correlation - Currency/Commodity

-0.46
( neutral )

-0.51
( weak negative )

0.00
( neutral )

-0.57
( weak negative )

0.37
( neutral )

Immix Biopharma, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-5 468.00 (0.00 %)
EPS:	$-0.890

FY	2023
Revenue:	$0
Gross Profit:	$-5 468.00 (0.00 %)
EPS:	$-0.890

FY	2022
Revenue:	$-89.52M
Gross Profit:	$-89.52M (100.00 %)
EPS:	$-0.620

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2 907.85

Financial Reports:

No articles found.

Immix Biopharma, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Immix Biopharma, Inc.

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.